Understanding how MRCK proteins affect ovarian cancer growth and spread
Official title: Interrogating MRCK Protein Kinases in Ovarian Cancer
Funded at Research Inst of Fox Chase Can Ctr · NIH-11030824 · Data updated 2026-11-12
This study is looking at how certain proteins called MRCKs help ovarian cancer cells grow and spread, with the goal of finding new treatments that could stop these cells from moving around and causing more problems for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $406,720 |
| NIH project number | 5R01CA282766-02 |
| Project ID | NIH-11030824 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with recurrent ovarian cancer, particularly those experiencing ascites.
✕Less likely to help
Patients with early-stage ovarian cancer or those whose cancer is not recurrent may not benefit from this research.
What this research studies
This research investigates the role of MRCK protein kinases in the growth and metastasis of ovarian cancer cells, particularly focusing on how these proteins influence the formation of spheroids in the peritoneal cavity. By studying the mechanisms of MRCKs, the research aims to develop new therapies that inhibit these proteins, potentially blocking cancer cell migration and invasion. The approach includes examining the actin cytoskeleton and its interactions with MRCKs to understand their contribution to ovarian cancer progression. Patients may benefit from new treatment options that target these specific pathways.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that improve outcomes for patients with recurrent ovarian cancer.
How similar studies have gone: Previous research has shown promise in targeting similar protein kinases for cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Duncan, James Stuart — Research Inst of Fox Chase Can Ctr
- Study coordinator: Duncan, James Stuart
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.